Topical neurokinin-1 receptor antagonist Fosaprepitant ameliorates ocular graft-versus-host disease in a preclinical mouse model.
Romina Mayra Lasagni Vitar, Filippo Bonelli, Ayça Atay...
https://pubmed.ncbi.nlm.nih.gov/34740637/Actively Recruiting
Led by Institut National de la Santé Et de la Recherche Médicale, France · Updated on 2026-07-07
110
Participants Needed
2
Research Sites
N/A
Total Duration
Rare Eye Diseases REDs affect the cornea, the transparent outer layer of the eye, disrupting its complex structure and leading to problems such as non-healing wounds, inflammation, scarring, and vision loss. This project aims to study seven different REDs, including genetic and autoimmune conditions, by analyzing gene and protein expression in patient tissues and fluids. It seeks to understand disease mechanisms and evaluate novel and repurposed drug targets to improve treatments for these rare conditions, which currently have limited effective options. The study involves recruiting adult participants with REDs and healthy controls. It collects blood, tear fluid, and conjunctival cell samples to analyze gene and protein levels linked to the diseases and the drugs being tested. Participants undergo ophthalmological exams, complete questionnaires about eye symptoms and pain, and provide biological samples through non-invasive procedures. The research compares expression patterns between patients and controls to identify biomarkers and correlations with clinical signs. Participants will attend an inclusion visit where clinical assessments, imaging, and sample collections occur. Researchers will monitor gene and protein expression levels to better understand REDs and the effects of potential treatments. The study involves no drug administration but focuses on validating targets for future therapies. Participation includes questionnaires, eye exams, and sample collection, with total involvement lasting the duration of study visits around the inclusion timepoint.
CONDITIONS
Identification of Cellular Biomarkers of Rare Eye Diseases in Adults
F
Francine Behar-Cohen, PU-PH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Institut National de la Santé Et de la Recherche Médicale, France
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit
Duration - 1 day
Participants undergo ophthalmological examinations, complete questionnaires, and provide blood, tear fluid, and conjunctival cell samples for gene and protein expression analysis.
1 visit
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Romina Mayra Lasagni Vitar, Filippo Bonelli, Ayça Atay...
https://pubmed.ncbi.nlm.nih.gov/34740637/Tanja Stachon, Claudia Fecher-Trost, Lorenz Latta...
https://pubmed.ncbi.nlm.nih.gov/38130099/Institut National de la Santé Et de la Recherche Médicale, France
Lead Sponsor